Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Kerr, Kathleen M. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S802000, C514S834000, C530S350000, C530S380000, C530S383000, C930S010000, C930S100000
Reexamination Certificate
active
07041635
ABSTRACT:
The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.
REFERENCES:
patent: 5399670 (1995-03-01), Bhattacharya et al.
patent: 2002/0132306 (2002-09-01), Kaufman et al.
patent: WO 00/24759 (2000-05-01), None
patent: WO 02/102850 (2002-12-01), None
Langner et al., “Synthesis of biologically active deletion mutants of human factor VIII:C”, Behring Inst Mitt. 1988 Apr;(82):16-25.
Nesheim et al., “The Effect of Plasma von Willebrand Factor on the Binding of Human Factor VIII to Thrombin-activated Human Platelets”, The Journal of Bioiogical Chemistry 1991, 266(27):17815-17820.
Sandberg et al., “Structural and functional characterization of B-domain deleted recombinant factor VIII”, Semin Hematol. 2001 Apr;38(2 Suppl 4):4-12.
Krishnan et al., “Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII delta II”, Eur J Biochem. 1991 Feb 14;195(3):637-44.
Lind et al., “Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization”, Eur J Biochem. Aug. 15, 1995;232(1):19-27.
Bihoreau et al., “Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain”, Biochem J. Jul. 1, 1991;277 ( Pt 1):23-31.
Haack et al., “Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines”, Ann Hematol 1999, 78:111-116.
Herlitschka et al., “High expression of a B-domain deleted factor VIII gene in a human hepatic cell line”, Journal of Biotechnology 1998, 61:165-173.
Sandberg et al., “Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ”, Thromb Haemost. Jan. 2001; 85(1):93-100.
Pipe and Kaufman, “Characterization of a genetically engineered inactivation resistant coagulation factor VIIIa”, Proc. Natl. Acad. Sci. USA Oct. 1997, 94:11851-11856.
Brinkhous, K.M. et al., 1985,Proc. Natl. Acad. Sci. USA, 82:8752-8756.
Burke, R.L. et al., 1986,J. Biol. Chem., 261(27):12574-12578.
Burton, M. et al., 1999,Proc. Natl. Acad. Sci. USA, 96(22):12725-12730.
Chiang, G.G. et al., 1999,Human Gene Therapy, 10:61-76.
Donath, M.J. et al., 1995,Biochem. J., 312:49-55.
Eaton, D. et al., 1986,Biochemistry, 25:505-512.
Eaton, D. et al., 1986,Biochemistry, 25:8343-8347.
Esmon, P.C., et al., 1990,Blood, 76(8):1593-1600.
Fay, P.J. et al., 1986,Biochem. Biophys. Acta, 871:268-278.
Fay, P.J. et al., 1991,J. Biol. Chem.,266(14):8957-8962.
Girma, J.P. et al., 1987,Blood, 70(3):605-611.
Koedam, J.A. et al., 1990,Eur. J. Biochem., 189:229-234.
Koller, B.H. and Smithies, O., 1989,Proc. Natl. Acad. Sci. USA, 86:8932-8935.
Michnick, D.A. et al., 1994,J. Biol. Chem., 269(31):20095-20102.
Pavirani, A. et al., 1987,Biochem Biophys Res Commun., 145(1):234-240.
Pittman, D.D. & Kaufman, R. J. 1988,Proc. Natl. Acad. Sci. USA, 85:2429-2433.
Pittman, D.D. et al., 1993,Blood, 81(11):2925-2935.
Toole, J.J. et al., 1984,Nature, 312:342-347.
Toole, J.J. et al., 1986,Proc. Natl. Acad. Sci. USA, 83:5939-5942.
Vehar, G.A. et al., 1984,Nature, 312:337-342.
Veltkamp, J.J. et al., 1968,Thromb. Diath. Haemorrh.,19(1):279-303.
Wu, G.Y. and Wu, C.H., 1987,J. Bio. Chem., 262(10):4429-4432.
Zijlstra et al., 1989,Nature, 342:435-438.
Bang Yung-Jue
Choi Jae Won
Jang Jin-Wook
Kim Dae-Kee
Kim Hun-Taek
In2Gen Co., Ltd.
JHK Law
Kerr Kathleen M.
Kim Joseph H.
Schnizer Holly
LandOfFree
Factor VIII polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor VIII polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VIII polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532736